Real-time quantification of multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide [1]

Haematologica

Volumn 87, Issue 10, 2002, Pages 1109-1111

  Au, Wing Y ^a   Chim, Chor Sang ^a   Lie, Albert Kwok Wai ^a   Pang, Annie ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Acute promyelocytic leukemia; Arsenic trioxide; Multidrug resistance

Indexed keywords

ARSENIC TRIOXIDE; GLUTATHIONE; GLYCOPROTEIN P; IDARUBICIN; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC CODE; HUMAN; LETTER; MALE; MOLECULAR CLONING; PEDIGREE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMYELOCYTIC LEUKEMIA; TREATMENT OUTCOME; UPREGULATION;

ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, MDR; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; P-GLYCOPROTEIN; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0036797142     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-60.
2. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-8.
3. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94:3315-24.
4. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19:3852-60.
5. Michieli M, Damiani D, Ermacora A, Geromin A, Michelutti A, Masolini P, et al. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol 2000; 108:703-9.
6. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66:274-9.
7. Au WY, Chim CS, Lie AKW, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002; 117:130-2.
8. Zhang W, Ling V. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J Cell Physiol 2000; 184:17-26.
9. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999; 81:796-9.
10. 3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol 2001; 66:357-64.